Renal Cell-State Mapping in Chronic Kidney Disease: Integrative Insights for Diagnosis and Treatment

Abstract

Chronic kidney disease (CKD) is characterized by progressive and irreversible nephron loss, which leads to significant morbidity and mortality worldwide. Recent advances in single-cell and spatial transcriptomics have enabled new approaches for renal cell-state mapping, providing unprecedented insight into the cellular heterogeneity and dynamic alterations that underlie CKD progression. This article presents an in-depth review of the current landscape in renal cell-state mapping, highlighting its epidemiological significance, underlying pathophysiology, risk factors, clinical manifestations, diagnostic approaches, management strategies, and recent therapeutic advances. The review underscores the clinical implications of cell-state mapping for improved disease stratification, personalized treatment, and future directions in nephrology.

Introduction

Chronic kidney disease is a major global public health challenge, affecting approximately 10% of the adult population. The pathogenesis of CKD is complex and multifactorial, involving diverse cellular and molecular mechanisms that lead to progressive fibrosis, inflammation, and loss of renal function. Traditional histopathological methods provide limited resolution regarding the cellular and molecular changes occurring in CKD. The advent of renal cell-state mapping technologies, such as single-cell RNA sequencing and spatial transcriptomics, has revolutionized our understanding of kidney biology in health and disease. These technologies offer granular insight into the cellular landscape, lineage plasticity, and dynamic state transitions that occur during CKD progression, with profound implications for diagnosis, prognosis, and therapy.

Epidemiology / Disease Burden

CKD represents a substantial disease burden globally, with an estimated prevalence of 8-16% in adults. The disease is associated with increased risk of cardiovascular events, mortality, and progression to end-stage renal disease (ESRD), necessitating renal replacement therapy. The World Health Organization recognizes CKD as a leading cause of morbidity, with a disproportionate impact on vulnerable populations and low- to middle-income countries. The economic and social consequences are significant, due to high costs of management and the need for lifelong care. Renal cell-state mapping initiatives, such as those undertaken by the Human Cell Atlas and the Kidney Precision Medicine Project (KPMP), aim to elucidate the cellular basis of CKD, potentially transforming epidemiological assessment and public health interventions.

Pathophysiology

The pathophysiology of CKD is driven by complex interactions among various renal cell types, including podocytes, tubular epithelial cells, endothelial cells, fibroblasts, and infiltrating immune cells. Cell-state mapping has revealed that injury triggers maladaptive responses, such as epithelial-to-mesenchymal transition (EMT), dedifferentiation of tubular cells, activation of myofibroblasts, and persistent inflammation. These processes contribute to interstitial fibrosis, glomerulosclerosis, and microvascular rarefaction. Single-cell analyses have identified distinct subpopulations of cells with unique transcriptomic signatures, implicating specific cell states in the progression or amelioration of CKD. Understanding these dynamic cell states enables the identification of novel therapeutic targets and biomarkers.

Risk Factors

Major risk factors for CKD include diabetes mellitus, hypertension, cardiovascular disease, obesity, aging, family history, and exposure to nephrotoxic agents. Genetic predisposition, such as APOL1 risk variants in individuals of African ancestry, also plays a role. Recent cell-state mapping work suggests that genetic and environmental risk factors may influence the vulnerability of specific renal cell types, modulate their response to injury, and determine disease trajectory. Identification of at-risk cell states may facilitate earlier intervention and risk stratification in clinical practice.

Clinical Features

CKD often progresses silently, with early stages being asymptomatic. Clinical manifestations emerge as renal function declines, including fatigue, edema, hypertension, anemia, mineral bone disorders, and, ultimately, uremic symptoms in advanced stages. Cell-state mapping studies have correlated specific cellular changes with clinical phenotypes, such as loss of podocyte integrity in proteinuric nephropathies or expansion of activated fibroblasts in fibrotic kidneys. These findings underscore the relevance of cell-state alterations in the development of clinically significant features and complications.

Diagnosis

The diagnosis of CKD is based on reduced glomerular filtration rate (GFR), albuminuria, and supportive imaging or histopathological findings. Traditional kidney biopsy provides valuable information, but is limited by sampling bias and inability to resolve cellular heterogeneity. Integrating cell-state mapping with routine diagnostics enables deeper molecular characterization of renal biopsies, identification of disease-specific cell states, and potential discovery of non-invasive biomarkers. Urinary exosomes and circulating cell-free RNA derived from specific renal cell states are emerging as promising diagnostic tools, offering potential for earlier and more precise detection of CKD.

Treatment & Management

Current management of CKD focuses on controlling underlying risk factors, slowing disease progression, and managing complications. Renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and blood pressure optimization are cornerstone therapies. Cell-state mapping has identified novel pathways involved in fibrosis, inflammation, and tubular regeneration, opening avenues for targeted interventions. For example, modulation of maladaptive tubular cell states or inhibition of profibrotic myofibroblast activation may complement existing therapies and improve patient outcomes.

Recent Advances / Emerging Therapies

Innovative therapies informed by renal cell-state mapping are rapidly emerging. Antifibrotic agents, immune modulators, and gene therapies targeting specific cell states are under investigation in preclinical and early clinical trials. Advances in spatial transcriptomics allow for the identification of pathogenic cell neighborhoods and intercellular signaling networks, enabling precision targeting of disease-driving processes. The identification of regenerative cell states also raises the prospect of kidney repair and functional restoration in early-stage CKD. These therapies hold promise for transforming the current paradigm of CKD treatment.

Guideline Recommendations

International guidelines, including those from KDIGO and the American Society of Nephrology, emphasize the importance of early detection, risk stratification, and individualized treatment in CKD management. The incorporation of molecular and cell-state data into clinical practice is evolving, with increasing recognition of the value of precision medicine approaches. Future guideline updates may incorporate validated cell-state biomarkers for risk assessment and therapeutic monitoring, reinforcing the importance of ongoing research in this field.

Conclusion

Renal cell-state mapping represents a paradigm shift in the understanding and management of chronic kidney disease. By delineating the complex cellular taxonomy and dynamic state transitions in the diseased kidney, these technologies offer new opportunities for improved diagnosis, risk stratification, and personalized therapy. Continued integration of cell-state mapping into clinical nephrology practice has the potential to address the unmet needs of CKD patients, reduce disease burden, and usher in a new era of precision medicine in nephrology.